IQ Consortium® Leadership

IQ's Board of Directors includes representatives from all IQ member companies and is led by a Chair and Vice-Chair.

Timothy Watson, Ph.D., Gilead Sciences
IQ Consortium Chair

Dr. Timothy Watson, Ph.D. is Vice President-Head of CMC Regulatory Affairs, Gilead Sciences. Prior to joining Gilead, Tim led Pfizer’s CMC Advisory Office, which is a collection of global Pfizer technical and regulatory experts that provides guidance and direction to project teams to mitigate regulatory risk and integrate CMC policy with product strategies, while developing and advocating policy positions (internally and externally) in conjunction with QO. The Advisory Office includes in-region team members to support AFME, LAT and AM, A-Pacific portfolio execution, and CMC policy, including Pfizer’s China’s CMC product portfolio team. In addition to Advisory Office responsibilities, Tim was instrumental in the development and implementation of Quality by Design, ICHQ12, etc., and advocated for global regulatory harmonization and mutual reliance, serving as a PhRMA representative to several ICH Expert and Implementation Working Groups (EWG and IWG) since 2009. Tim served as a PhRMA EWG member on the ICHQ11 regulatory guidance document for drug substance, the Rapporteur for the ICHQ11 Q and A Starting Material IWG, PhRMA IWG member for the ICHQ7 Q and A team, and continues to serve as the PhRMA ICHQ3C EWG lead. Tim was nominated as the PhRMA IWG/ EWG lead for ICHQ9 revision (starting in 2020). Tim serves on the Board of Directors for the International Consortium for Innovation and Quality (IQ), co-Chairs the ISPE Global Regulatory and Quality Harmonization Council and is a member of the Regulatory Steering Committee, and was Pfizer’s lead representative on the PhRMA Global Quality and Manufacturing Work Group (GQM WG). Tim authored numerous publications and presentations and received multiple awards for regulatory contributions (e.g., AAPS Regulatory Section Recognition Award in 2014).

Tim began his career at Marion Merrell Dow (1994) in chemical research and development (CRD) as an API small molecule process chemist, where his responsibilities involved developing new API processes, manufacturing the first GMP API bulk clinical supplies, and technology transfers to commercial facilities/ CROs, etc. In 2000, Tim joined Pfizer, where he continued with process chemistry development responsibilities with a focus on post-proof of concept projects and commercialization up until 2009, when he joined CMC. Tim holds a Ph.D. from The Ohio State University, under the direction of Dr. Leo Paquette


Philip Floyd, Ph.D., AbbVie
IQ Consortium Vice-Chair

Phil currently serves as Global VP, Analytical Research and Development at AbbVie overseeing a department of approximately 230 scientists in the development of the small molecule portfolio. Prior to AbbVie, he served as Senior Director of US Analytical Development at GSK overseeing both large and small molecule development in two sites within Pennsylvania. While at GSK, Phil also spent several years in RTP North Carolina at Team Leader with a mixed development team of formulators and analysts. Prior to this time Phil worked as bench analyst at both GSK and J&J.

Phil grew up in Oklahoma and received his BS in Chemistry at the University of Oklahoma. After graduation, he attended the University of Illinois at Urbana-Champaign and received his PhD in Analytical Chemistry under Jonathan Sweedler.  While at Illinois, he performed the research for his dissertation at the Beckman Institute of Technology, working collaboratively with varying disciplines, such as Molecular and Cellular Biology, Computational Chemistry, Engineering, and Physical Chemistry, in performing quantitative analysis and characterization of peptides and proteins within neuronal signaling pathways. 

Phil has over 40 scientific presentations over 20 publications in peer-reviewed journals. He currently serves as Vice-Chair on the IQ Consortium Board of Directors.